Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIRECTION Study
2025-524495-39-00Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of dupilumab and tezepelumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Change in nasal polyp score (NPS) or SNOT-22 from baseline to 12 months. Planned start Mar 2026; status: authorised.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2025-524495-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524495-39-00.